New Health Sciences has closed a $1.5 million Series A financing raised from existing private investors. NHSi will use the new capital to fund continued development of its Hemanext technology.
Dr. Larry Dumont of Dartmouth-Hitchcock Medical Center will present a paper by Dr. Dumont and Dr. Tatsuro Yoshida (New Health Sciences’ Hemanext R&D director) entitled CO2 effects during anaerobic storage of RBC at the AABB’s
New Health Sciences Files Investigational New Device (IND) Application with US Food and Drug Administration
New Health Sciences has filed its IND application for the Hemanext Anaerobic Storage Platform (HASP) with the U.S. Food and Drug Administration. HASP is a disposable device that de-oxygenates red blood cells at the point
The National Blood Foundation has awarded Tulane University (Dr. Sergey Shevkoplyas) a $75,000 grant for phase I research and development of NHSi’s Microvascular Analyzer (MVA) technology. MVA is a network of micro-channels etched into a
In an editorial published in the journal Blood Transfusion, Dr. James AuBuchon (President and CEO, Puget Sound Blood Bank, and Professor of Medicine and Laboratory Medicine, Univeristy of Washington) and Dr. Giancarlo Maria Liumbruno (Research
Hemanext Research Presented at the XXXIX Convegno Nazionale di Studi di Medicina Transfusionale in Milan, Italy
New Health Sciences’ Hemanext R&D director, Dr. Tatsuro Yoshida presented a talk entitled “New Models for Blood Storage” at the XXXIX Convegno Nationale di Studi di Medicina Transfusionale, in Milan, Italy. The review of anaerobic
New Health Sciences has closed a $2.6 million Series A financing raised from a combination of new and existing private investors. NHSi will use the new capital to fund continued development of its Hemanext technology.
New Health Sciences’ Hemanext R&D director, Dr. Tatsuro Yoshida presented the results of NHSi’s research in the field of anaerobic storage of red blood cells at the Blood and Proteomics Conference in Viterbo, Italy.